STERIS /$STE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About STERIS

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Ticker

$STE

Primary listing

NYSE

Industry

Health Care Equipment and Supplies

Employees

17,787

STERIS Metrics

BasicAdvanced
$22B
36.05
$6.21
0.94
$2.28
1.02%

What the Analysts think about STERIS

Analyst ratings (Buy, Hold, Sell) for STERIS stock.

Bulls say / Bears say

STERIS reported a 6% year-over-year increase in total revenue for Q3 2025, reaching $1.4 billion, surpassing analyst expectations. (gurufocus.com)
The Healthcare segment, STERIS's largest revenue contributor, grew by 7% to $976 million in Q3 2025, driven by a 9% increase in consumable revenue and 13% growth in service revenue. (gurufocus.com)
STERIS's Applied Sterilization Technologies (AST) segment experienced a 10% revenue increase to $258.1 million in Q3 2025, reflecting strong service revenue growth. (gurufocus.com)
STERIS's Life Sciences segment saw a 7% revenue decline to $136.4 million in Q3 2025, primarily due to divestitures and a decrease in capital equipment revenue. (gurufocus.com)
The company faces challenges from supply-chain constraints, higher material costs, and ongoing labor inflation, which have significantly impacted its margins. (nasdaq.com)
With nearly 30% of its revenues generated outside the United States, STERIS is exposed to foreign currency exchange rate fluctuations, which can significantly impact its financial position and competitive stance. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

STERIS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

STERIS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $STE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs